Here, we review the discovery and biology of oncogenic ALK and ROS1 rearrangement and summarize several pivotal clinical trials that validated crizotinib as a therapeutic agent for NSCLC. This evidence concerns the gene ROS1 and non-small cell lung carcinoma.